Jed Dorsheimer, William Blair analyst, joins 'The Exchange' to discuss Tesla's chip deal with Samsung and what it means for ...

In its own communique issued shortly after the FDA’s, Sarepta elaborated on the situation and confirmed a Roche statement to ...

Vertiv Holdings (NYSE:VRT) on Monday was rated Outperform in new research coverage by analysts at investment firm William ...

Brazilian authorities said the death was unlikely to have been caused by Elevidys and was instead more in line with severe ...

In addition, The Allstate Corporation (NYSE:ALL) is taking advantage of a far better auto loss environment and employing ...

The company didn’t share specific data for the molecule, gefurulimab, but said it hit all endpoints in the Phase III PREVAIL ...

Local news on this date July 26, 1950 Company D, 6th infantry battalion, U.S. Marine Corps Reserves, Capt. William C. Bell commanding, became the third Blair County military reserve unit to be called ...

William Blair analysts lowered their rating on Ameriprise stock to Market Perform from Outperform Friday following the financial services firm’s second-quarter report.

Sarepta and Roche face a regulatory setback as the EMA's CHMP issues a negative opinion on Elevidys for Duchenne muscular ...

The administration has repeatedly criticized Jerome H. Powell, the chair of the central bank, for his handling of the economy and the cost of work on the institution’s headquarters.

Wall Street analysts warn that if Sarepta Therapeutics doesn't resolve the Elevidys issues, it could jeopardize its ability to repay debt in 2027.

Meanwhile, Tesla's brand image is absolutely cooked. Plus, The U.S. built fewer than 400 chargers with $7.5 billion in ...